Opinion|Videos|March 4, 2024
Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer
A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.
Advertisement
Episodes in this series
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film
2
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
3
Pulmonary Fibrosis and Sexual Health: A Q&A With Na’ama Avitzur, MD
4
Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024
5
